A Randomized, Double-Blind, Parallel, Multicenter, Two-Arm Study to Compare the Pharmacokinetics, Safety, and Immunogenicity Between Bmab1700 and Opdivo® After Complete Resection of Stage IIB/C, Stage III, or Stage IV Melanoma
Latest Information Update: 25 Mar 2026
At a glance
- Drugs Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Biocon Biologics
Most Recent Events
- 25 Mar 2026 New trial record